参考文献：（上下滑动查看更多）

[1] Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021 Aug 28;398(10302):759-771.

[2] Luo  H, Lu  J, Bai  Y,  et al.  Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial.   JAMA. Published online September 14, 2021.

[3] DaSilva LL, Aguiar PN, de Lima Lopes G. Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge. JAMA Oncol. 2021;7(11):1613–1614.

[4] Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology, 2021 Aug; 22(8): 1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23. PMID: 34174189.

[5] Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature Medicine, 2021 Sep; 27(9): 1536-1543. doi: 10.1038/s41591-021-01444-0. Epub 2021 Aug 2. PMID: 34341578.

[6] 2021 ASCO LAB 2.

[7] Cheng A L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021 Dec 10:S0168-8278(21)02241-8.

[8] CT009 - IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

[9] Qin S K, Ren Z G, Feng Y X, et al. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer. 2021 Jul;10(4):296-308.

[10] Finn RS, Qin S, Ikeda M, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). 2021ASCO GI，abs267.

[11] Ren Z G, Xu J M, Bai Y X, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. The Lancet Oncology. 2021, 22(7): 977-990.

[12]Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al. Durvalumab,with or without tremelimumab,plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.The Lancet Oncology.2020.

[13]Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia.2019 ESMO ASIA.

[14]Jonathan W G , Marina C G, Yuanbin Chen,et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 Nov;149:46-52.

[15]https://mp.weixin.qq.com/s/8eiE_5-f_1R658cuhw_z5Q